1,872
Views
2
CrossRef citations to date
0
Altmetric
Research Article

The Effects of a Multiday (10–14 days) Subanesthetic Dose IV Ketamine Infusion in the Treatment of Refractory Chronic Pain

, ORCID Icon, , , , & show all
Pages 337-346 | Received 30 Jun 2021, Accepted 31 Aug 2021, Published online: 16 Sep 2021

References

  • Noppers I , NiestersM , AartsL , SmithT. Ketamine for the treatment of chronic noncancer pain. Expert Opin. Pharmacother.11(14), 2417–2429 ( 10AD).
  • Bell RF , KalsoEA. Ketamin in der Schmerztherapie. Der Schmerz.33(2), 156–164 (2019).
  • Hilal-Dandan R , BruntonLL , GoodmanLS. Goodman and Gilman’s Manual of Pharmacology and Therapeutics.Hilal-DandanR, BruntonLL (Eds). 2nd ed. McGraw-Hill, NY, USA.
  • Bennett GJ . Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J. Pain Symptom Manage.19(1), 2–6 (2000).
  • Yanagihara Y , OhtaniM , KariyaSet al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm. Drug Dispos.24(1), 37–43 (2003).
  • Olofsen E , NoppersI , NiestersMet al. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology117(2), 353–364 (2012).
  • Bell RF , DahlJB , MooreRA , KalsoE. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol. Scand.49(10), 1405–1428 (2005).
  • Maher DP . Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth. Analg.124(2), 661–674 ( 2AD).
  • Sigtermans MJ , van HiltenJJ , BauerMCRet al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain145(3), 304–311 (2009).
  • Amr YM . Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician13(3), 245–249 (2010).
  • Schwartzman RJ , AlexanderGM , GrothusenJR , PaylorT , ReichenbergerE , PerreaultM. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain147(1–3), 107–115 (2009).
  • Bredlau AL , ThakurR , KoronesDN , DworkinRH. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med.14(10), 1505–1517 (2013).
  • Lauretti GR , LimaIC , ReisMP , PradoWA , PereiraNL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology90(6), 1528–1533 (1999).
  • Yang C-Y , WongC-S , ChangJ-Y , S-THO , SevarinoFB. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Surv. Anesthesiol.41(5), 305 (1997).
  • Lauretti GR , GomesJMA , ReisMP , PereiraNL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J. Clin. Anesth.11(8), 663–668 (1999).
  • Zekry O , GibsonSB , AggarwalA. Subanesthetic, subcutaneous ketamine infusion therapy in the treatment of chronic nonmalignant pain. J. Pain Palliat. Care Pharmacother.30(2), 91–98 (2016).
  • Busse JW , CraigieS , JuurlinkDNet al. Guideline for opioid therapy and chronic noncancer pain. Can. Med. Assoc. J.189(18), LP–E666 (2017).
  • https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf
  • Rennick A , AtkinsonT , CiminoNM , StrasselsSA , McPhersonML , FudinJ. Variability in opioid equivalence calculations: variability in opioid equivalence. Pain Med.n/a–n/a (2015).
  • Li Y , KantelipJ-P , SchieveenPG , DavaniS. Interindividual variability of methadone response: impact of genetic polymorphism. Mol. Diagn. Ther.12(2), 109–124 (2008).
  • Farrar JT , YoungJP , LaMoreauxL , WerthJL , PooleRM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain94(2), 149–158 (2001).
  • Cohen SP , BhatiaA , BuvanendranAet al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg. Anesth. Pain Med.43(5), 521–546 (2018).
  • Finnerup NB , HaroutounianS , KamermanPet al. Neuropathic pain: an updated grading system for research and clinical practice. Pain157(8), 1599–1606 (2016).
  • Tran K , McCormackS. Ketamine for Chronic noncancer Pain: A Review of Clinical Effectiveness, Cost–Effectiveness, and Guidelines.Canadian Agency for Drugs and Technologies in Health, ON, Canada.
  • Orhurhu V , OrhurhuMS , BhatiaA , CohenSP. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth. Analg.129(1), 241–254 (2019).
  • Michelet D , BrasherC , HorlinALet al. Ketamine for chronic noncancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. J. Pain (United Kingdom).22(4), 632–646 (2018).
  • Wu MD L , HuangMD X , SunMD L. The efficacy of N-methyl-D-aspartate receptor antagonists on improving the postoperative pain intensity and satisfaction after remifentanil-based anesthesia in adults: a meta-analysis. J. Clin. Anesth.27(4), 311–324 (2015).
  • Marchetti F , CoutauxA , BellangerA , MagneuxC , BourgeoisP , MionG. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5-year study of 51 patients: Oral ketamine for intractable pain. Eur. J. Pain.19(7), 984–993 (2015).